Cold water immersion did not accelerate recovery after a futsal match

© 2014, Redprint Editora Ltda. All rights reserved. Introduction: cold-water immersion (CWI) is a popular recovery strategy; however, there is limited evidence of the effectiveness of this method in sport settings. Objective: to investigate the effect of CWI on muscle soreness and anaerobic performance after a Futsal match. Methods: ten players performed two simulated matches followed by two randomized recovery conditions (CWI or passive rest - C), separated for seven days. During the recovery interventions, the players remained seated in a comfortable position (C) or were immersed in a pool with cold water (CWI condition; 15±1ºC) for 12 minutes. Muscle soreness assessment, counter movement jump (CMJ) test, repeated jump ability (RJA) test, and repeated sprint running test (rRST) were conducted prior to the match (Pre), immediately after the recovery intervention (P1) and 24h after the recovery intervention (P2). Results: a significant increase in muscle soreness after the Futsal match was observed for both interventions (C and CWI) during all time points (P1 and P2, p0.05). There was a significant decrease in anaerobic performance (CMJ, RJA and rRST) immediately after the CWI intervention when compared to C (P1, p0.05). Conclusion: the CWI did not improve recovery related to muscle soreness and anaerobic performance of Futsal players

Long-term tobacco exposure and immunosenescence: paradoxical effects on T-cells telomere length and telomerase activity

Immunosenescence are alterations on immune system that occurs throughout an individual life. The main characteristic of this process is replicative senescence, evaluated by telomere shortening. Several factors implicate on telomere shortening, such as smoking. In this study, we evaluated the influence of smoking and Chronic Obstructive Pulmonary Disease (COPD) on cytokines, telomere length and telomerase activity. Blood samples were collected from subjects aged over 60 years old: Healthy (never smokers), Smokers (smoking for over 30 years) and COPDs (ex-smokers for ≥15 years). A young group was included as control. PBMCs were cultured for assessment of telomerase activity using RT-PCR, and cytokines secretion flow cytometry. CD4+ and CD8+ purified lymphocytes were used to assess telomere length using FlowFISH. We observed that COPD patients have accelerated telomere shortening. Paradoxically, smokers without lung damage showed preserved telomere length, suggesting that tobacco smoking may affect regulatory mechanisms, such as telomerase. Telomerase activity showed diminished activity in COPDs, while Smokers showed increased activity compared to COPDs and Healthy groups. Extracellular environment reflected this unbalance, indicated by an anti-inflammatory profile in Smokers, while COPDs showed an inflammatory prone profile. Further studies focusing on telomeric maintenance may unveil mechanisms that are associated with cancer under long-term smoking

HLA-C stability and AIDS progression

HLA-C stability influence AIDS progressio

Geo-environmental mapping using physiographic analysis: constraints on the evaluation of land instability and groundwater pollution hazards in the Metropolitan District of Campinas, Brazil

Geo-environmental terrain assessments and territorial zoning are useful tools for the formulation and implementation of environmental management instruments (including policy-making, planning, and enforcement of statutory regulations). They usually involve a set of procedures and techniques for delimitation, characterisation and classification of terrain units. However, terrain assessments and zoning exercises are often costly and time-consuming, particularly when encompassing large areas, which in many cases prevent local agencies in developing countries from properly benefiting from such assessments. In the present paper, a low-cost technique based on the analysis of texture of satellite imagery was used for delimitation of terrain units. The delimited units were further analysed in two test areas situated in Southeast Brazil to provide estimates of land instability and the vulnerability of groundwater to pollution hazards. The implementation incorporated procedures for inferring the influences and potential implications of tectonic fractures and other discontinuities on ground behaviour and local groundwater flow. Terrain attributes such as degree of fracturing, bedrock lithology and weathered materials were explored as indicators of ground properties. The paper also discusses constraints on- and limitations of- the approaches taken

Deletion of ameloblastin exon 6 is associated with amelogenesis imperfecta

Amelogenesis imperfecta (AI) describes a heterogeneous group of inherited dental enamel defects reflecting failure of normal amelogenesis. Ameloblastin (AMBN) is the second most abundant enamel matrix protein expressed during amelogenesis. The pivotal role of AMBN in amelogenesis has been confirmed experimentally using mouse models. However, no AMBN mutations have been associated with human AI. Using autozygosity mapping and exome sequencing, we identified genomic deletion of AMBN exon 6 in a second cousin consanguineous family with three of the six children having hypoplastic AI. The genomic deletion corresponds to an in-frame deletion of 79 amino acids, shortening the protein from 447 to 368 residues. Exfoliated primary teeth (unmatched to genotype) were available from family members. The most severely affected had thin, aprismatic enamel (similar to that reported in mice homozygous for Ambn lacking exons 5 and 6). Other teeth exhibited thicker but largely aprismatic enamel. One tooth had apparently normal enamel. It has been suggested that AMBN may function in bone development. No clinically obvious bone or other co-segregating health problems were identified in the family investigated. This study confirms for the first time that AMBN mutations cause non-syndromic human AI and that mouse models with disrupted Ambn function are valid

Psychometric Evidence of The 7-Item Generalized Anxiety Disorder Questionnaire in Brazil

Generalized Anxiety Disorder (GAD) is one of the most prevalent and 1 impairing psychological disorders. GAD is defined as a persistent and excessive worry 2 associated with physical and psychological symptoms. Despite the potentially severe 3 nature of GAD, it has been estimated that nearly half of patients live with the symptoms 4 for about two years before being appropriately diagnosed and treated. To allow early 5 identification of this disorder, valid and reliable measures for the screening of GAD are 6 essential. Therefore, the present study aimed to gather psychometric evidence of the 7-7 Item Generalized Anxiety Disorder Questionnaire (GAD-7) in Brazil (N = 746). The 8 findings suggested a stable one-factor structure (CFI = .99; TLI = .99; RMSEA = .05) 9 that is likely to be replicated (H-Latent = .92; H-Observed = .86) and have excellent 10 reliability (ω = .91; CR = .91). Furthermore, the GAD-7 correlated positively with the 11 DASS-21 stress (r = .73), depression (r = .53), and anxiety (r = .60) factors, along with 12 the Groningen Sleep Quality Scale (r = .45) and the personality trait of neuroticism (r = 13 .49), supporting its convergent validity. Finally, the GAD-7 is able to differentiate 14 between participants with mild, moderate and severe level of anxiety. Taken together, 15 the present findings indicate that the GAD-7 is a suitable psychometric measure to 16 assess generalized anxiety disorder in Brazil

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial

Importance: Catechol O-methyltransferase (COMT) inhibitors are an established treatment for end-of-dose motor fluctuations associated with levodopa therapy in patients with Parkinson disease (PD). Current COMT inhibitors carry a high risk for toxic effects to hepatic cells or show moderate improvement. Opicapone was designed to be effective without the adverse effects. Objective: To evaluate the efficacy and safety of 25- and 50-mg/d dosages of opicapone compared with placebo as adjunct to levodopa therapy in patients with PD experiencing end-of-dose motor fluctuations. Design: This phase 3 international, multicenter outpatient study evaluated a 25- and a 50-mg/d dosage of opicapone in a randomized, double-blind, 14- to 15-week, placebo-controlled clinical trial, followed by a 1-year open-label phase during which all patients received active treatment with opicapone. Patients with PD who experienced signs of end-of-dose deterioration and had a mean total awake off-time (state of akinesia or decreased mobility) of at least 1.5 hours, not including morning akinesia, were enrolled. Data were collected from March 18, 2011, through June 25, 2013. Data from the evaluable population were analyzed from July 31, 2013, to July 31, 2014. Main Outcomes and Measures: The primary efficacy outcome of the double-blind phase was the change from baseline in absolute off-time vs placebo based on patient diaries. The open-label phase focused on maintenance of treatment effect in off-time. Results: A total of 427 patients (258 men [60.4%] and 169 women [39.6%]; mean [SD] age, 63.1 [8.8] years) were randomized to a 25-mg/d (n = 129) or a 50-mg/d (n = 154) dosage of opicapone or to placebo (n = 144). Of these, 376 patients completed the double-blind phase and entered the open-label phase, of whom 286 completed 1 year of open-label treatment. At the end of the double-blind phase, the least squares mean change (SE) in off-time was -64.5 (14.4) minutes for the placebo group, -101.7 (14.9) minutes for the 25-mg/d opicapone group, and -118.8 (13.8) minutes for the 50-mg/d opicapone group. The adjusted treatment difference vs placebo was significant for the 50-mg/d opicapone group (treatment effect, -54.3 [95% CI, -96.2 to -12.4] minutes; P = .008), but not for the 25-mg/d opicapone group (treatment effect, -37.2 [95% CI, -80.8 to 6.4] minutes; P = .11). The off-time reduction was sustained throughout the open-label phase (-126.3 minutes at 1-year open-label end point). The most common adverse events in the opicapone vs placebo groups were dyskinesia, constipation, and dry mouth. Fifty-one patients (11.9%) discontinued from the study during the double-blind phase. Conclusions and Relevance: Treatment with a 50-mg once-daily dose of opicapone was associated with a significant reduction in mean daily off-time in levodopa-treated patients with PD and motor fluctuations, and this effect is maintained for at least 1 year. Opicapone was safe and well tolerated. Trial Registration: clinicaltrials.gov Identifier: NCT01227655

Synthesis of recrystallized anatase TiO2 mesocrystals with Wulff shape assisted by oriented attachment

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)In this work, we describe a kinetically controlled crystallization process assisted by an oriented attachment (OA) mechanism based on a nonaqueous sol-gel synthetic method (specifically, the reaction of titanium(IV) chloride (TiCl4) with n-octanol) to prepare re-crystallized anatase TiO2 mesocrystals (single crystal). The kinetics study revealed a multi-step and hierarchical process controlled by OA, and a high resolution transmission electron microscopy (HRTEM) analysis clearly shows that the synthesized mesocrystal presents a truncated bipyramidal Wulff shape, indicating that its surface is dominated by {101} facets. This shape is developed during the recrystallization step. The material developed here displayed superior photocatalytic activity under visible light irradiation compared to TiO2-P25 as a benchmarking.3419101916Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)FINEPConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)FAPESP [98/14324-0